Naturally-derived macrocyclic compounds are associated with a diverse range of biological activities, including antibacterial effects, and there are over 100 marketed macrocycle drugs derived from natural products. However, synthetic macrocycles are widely considered to be poorly explored in antibiotic development (indeed, within drug discovery in general). This has been attributed to challenges associated with the generation of such compounds. Whilst there are synthetic methods that can produce large collections of structurally similar macrocycles (i.e., compounds with varying appendages based around similar core macrocyclic ring architectures) there is a relative dearth of strategies for the efficient generation of more structurally diverse macrocycle collections in which there is greater variation in the nature of macrocyclic scaffolds present. Such macrocycle collections should contain compounds with a broad range of biological activities (including antibacterial activities) and the requisite robust synthetic methodology useful for analogue synthesis and lead optimization once an active compound has been identified in a biological screen. Herein, we describe a new and expedient diversity-oriented synthesis (DOS) strategy for the generation of a library of novel structurally diverse macrocyclic compounds with a high level of scaffold diversity. The strategy is concise, proceeds from readily-available starting materials, is modular in nature and features a variety of macrocyclisation techniques. In this proof-ofconcept study, the synthesis of several previously unreported macrocyclic compounds was achieved. Each of these macrocycles was based around a distinct molecular scaffold and contained natural productlike structural features (e.g., three-dimensionality and multiple hydrogen bond donors and acceptors) as well as synthetic handles for potential further elaboration. The successful generation of these macrocycles demonstrates the feasibility of the new DOS strategy as a synthetic platform for library generation.
Introduction
The inexorable rise in antibiotic-resistant bacteria has led to a steady decline in the efficacy of existing therapies for the treatment of bacterial infections.
1,2 Moreover, the pace at which new antibacterial agents are being generated has decreased dramatically in recent decades, a legacy of insufficient investment in fundamental antibacterial research by pharmaceutical companies since the 1960s. 1,2 Consequently, humanity is facing the very real and disturbing possibility of a future without an effective method for the treatment of some common bacterial infections. 1, 2 Thus, there is a clear and critical medical need for the discovery of novel antibiotics. 1, 3 Lead compounds for antibacterial chemotherapy can be obtained from two sources: nature (natural products) or de novo chemical synthesis. 1 Historically, nature has been by far the more important; most of the major classes of antibiotics in therapeutic use are natural products or semi-synthetic derivatives thereof. 1, 3 Among these, a macrocyclic scaffold (a ring system of 12 or more atoms) is common ( Fig. 1) . Indeed, naturally-derived macrocycles constitute a large class of compounds with useful antibacterial properties. 4e6 Natural macrocyclic derivatives are also associated with a broad range of other attractive biological effects (including anticancer, antifungal and immunosuppressive activities) 5,7 and there are more than 100 marketed macrocyle drugs derived from natural products. 8 The diverse and interesting biological activities associated with the macrocyclic compound class has been attributed to characteristic structural features. 7, 8 Their cyclic structure means that they have less conformational freedom than an equivalent acylic compound and so suffer a smaller entropic loss upon binding to a biological target. 7e9 However, unlike smaller cyclic systems, macrocycles retain a certain flexibility, allowing them to potentially mould to a target surface in order to maximize binding interactions. 7e9 In addition, macrocycles can potentially adopt conformations in which polar motifs are buried away, leading to improved membrane permeability relative to their linear analogues. 7 Clearly, macrocycles represent attractive targets in the search for new lead compounds for antibiotic development (indeed, drug development in general). 4, 7, 8 However, naturally occurring macrocycles are often highly complex in structure, which hampers their synthetic modification and pharmacokinetic optimization. 4, 7, 10 Thus, attention has shifted in recent years towards the exploration of synthetic macrocycles of medium complexity in drug discovery. 7, 10 There has been notable success in this field, with many biologically active synthetic macrocycles with appropriate pharmacokinetic profiles identified 10 (including antibacterial lead compounds 11, 12 ). However, despite these encouraging examples, synthetic macrocycles are still widely considered to be relatively underexplored within drug discovery in general. 7e10, 13 This has been attributed to challenges associated with the synthesis of such compounds, particularly in the context of the formation of the macrocyclic ring architecture. 7, 9 Where present in a small molecule, the macrocyclic ring is generally considered to serve as the molecular scaffold (i.e., the core rigidifying structural feature of a molecule). 14 Whilst there are synthetic methods that can produce large collections of structurally similar macrocycles (i.e., compounds with varying appendages based around similar core macrocyclic scaffolds) there is a relative dearth of strategies for the efficient generation of more structurally diverse macrocycle collections in which there is greater variation in the nature of macrocyclic scaffolds present. 10, 14 This is a crucial issue in the context of biological screening, since the overall structural, and thus functional diversity of a compound set (i.e., the range of biological activities displayed by the compounds) is known to be highly dependent upon the variety of molecular scaffolds present (the scaffold diversity) of the collection. 15e17 Macrocyclic collections with higher levels of scaffold diversity would be expected to provide a higher hit rate against a broader range of targets than libraries with lower scaffold, and thus overall structural, diversity. 14, 15 Scaffold diverse macrocycle collections would therefore be expected to be particularly valuable in biological screens where the nature of the biological target is unknown (e.g., in phenotypic screening). 15, 18 In addition, efficient access to structurally diverse macrocycles necessitates the development of synthetic methodology which is robust and broadly applicable in nature, which should facilitate the lead optimization process once a hit compound has been identified. 11, 19 Diversity-oriented synthesis (DOS) is a field of organic chemistry directed towards the efficient generation of molecular libraries that incorporate high degrees of structural diversity, including scaffold diversity. 15,20e22 The screening of DOS libraries has led to the identification of numerous novel biologically active small molecules, including several with antibacterial activities. 3,15,23e28 Recent years have seen the development of several DOS-type strategies specifically targeted at macrocyclic structures including examples from our own research group. 9,10,14,19,27,29e33 However, there remains considerable scope for further developments in the field. From a synthesis perspective, there are improvements that can be made in terms of the expediency of library construction and the efficiency in which scaffold diversity is generated. 19 In addition, large areas of macrocyclic chemical space, that may contain molecules with exciting biological properties (e.g., critically needed new antibacterials), still remain under-explored. These considerations highlight the need for new and expedient DOS strategies towards previously undescribed macrocyclic compounds. Herein, we describe work towards the development of one such strategy, which is based around the use of readily-accessible phenolic carbonyls as key starting materials. In a proof-of-concept study the synthesis of several structurally diverse and previously unreported macrocyclic scaffolds was achieved, which provides a validation of this DOS strategy as a synthetic platform for library generation.
Results and discussion

Outline of the synthetic strategy
Many DOS pathways are based around a three-phase build/ couple/pair (B/C/P) algorithm. 20 In the build phase, starting materials (or building blocks) are synthesized. These are then combined (coupled together) in the couple phase to yield densely functionalized substrates for the subsequent pair phase, which involves intramolecular reactions that join pairwise combinations of functional groups to generate distinct molecular scaffolds. 14, 20 In recent years, the use of iterative couple steps (i.e., B/C/C/P, B/C/C/C/P, etc.) has been exploited as a means to increase the diversity of scaffolds accessible from a given set of building blocks. 14, 34 For example, we have recently reported a DOS strategy towards macrocyclic peptidomimetic scaffolds that incorporates iterative couple steps. 14 It was thought that the iterative couple concept could be used as the basis for a new and expedient DOS strategy towards novel and diverse macrocyclic compounds. We conceived the use of readilyaccessible phenolic compounds of the general form 4, which bear an electrophilic carbonyl group and a nucleophilic hydroxyl group, as key starting materials (Scheme 1). It was hoped that each given aromatic compound would serve as a 'platform' onto which different building blocks (generated in the build phase of the DOS) could be attached through functionalisation of these two reactive sites (couple stages). This would then afford a range of distinct acyclic precursors, which could then undergo intramolecular reactions to furnish different macrocyclic compounds, each based around a distinct molecular scaffold (pair phases). More specifically, we envisaged the use of four general types of building blocks: the aforementioned aromatic 'platform' building blocks 4 (which would contain an aldehyde or a carboxylic acid moiety together with the hydroxyl group), together with 'hydroxyl capping' building blocks 5 and 6 'carbonyl capping' building blocks 7 and 8 (cyclic and acyclic amines in both cases) and malonic acid (9), a 'spacer' building block. It was anticipated that the 'platform' aromatic building blocks 4 could be functionalised at the hydroxyl position (a couple phase) by reaction with the appropriate 'hydroxyl capping' building block 5 or 6 to furnish compounds of the general form 10 and 11 (from aromatic carboxylic acids and aromatic aldehydes, respectively, Scheme 1). Subsequent functionalisation of the carbonyl moieties with the appropriate 'carbonyl capping' building block 7 or 8 (a couple phase) would generate compounds of the general form 12 (by amide bond formation from 10) and 13 (by reductive amination from 11). Compounds of the form 12 and 13 contain functional groups that could then potentially be reacted together intramolecularly in the subsequent pair phase of the DOS to access diverse macrocyclic scaffolds (B/C/C/P pathways).
Specifically, compounds 12 contain a terminal alkyne and terminal azide group; it was envisaged that a regioselective metal-catalysed 'click'-type 1,3-dipolar cycloaddition would thus furnish macrocyclic architectures of the general form 14 containing either 1,5-disubstituted triazoles (ruthenium catalysis) or 1,4-disubstituted triazoles (copper catalysis).
In the case of compounds 13, which contain two terminal alkene moieties, it was hoped that an intramolecular ring-closing metathesis reaction could be carried out to yield macrocyclic scaffolds of the general form 15. Furthermore, it was envisaged that largersized macrocyclic structures 16 could be accessed by extension of the aldehyde moiety of key branchepoint compounds 11 by an additional couple step with the 'spacer' building block 9 (a Knoevenagel condensation) to form compounds 17. Subsequent carbonyl capping with building blocks 8 would generate compounds 18 which contain a terminal alkene and a terminal alkyne. Ringclosing ene-yne metathesis would then furnish the target compounds 16 (the pair stage). This would formally constitute a B/C/C/ Scheme 1. Outline of the DOS strategy towards structurally diverse macrocyclic compounds of the general forms 14e16. The shaded shapes represent scaffold-defining elements (i.e., regions that can be varied to obtain different macrocyclic scaffolds).
LG¼a leaving group (e.g., a halogen).
C/P pathway. These larger-sized macrocycles may be better able to target extended binding interfaces (such as those associated with proteineprotein interactions) than the smaller-sized compounds resulting from a single couple step.
14, 35 Overall, we anticipated that the DOS strategy outlined in Scheme 1 would allow access to novel and structurally diverse macrocyclic compounds of three different structural forms 14e16. Several attractive features of the proposed DOS strategy were identified. It is step-efficient from readily available building blocks. Furthermore, it is inherently modular in nature. Thus, it was anticipated that high levels of structural diversity could be achieved in an expedient fashion through the use of a small set of building-blocks. Variation in the scaffold-defining elements of the building blocks should allow for efficient generation of scaffold diversity within each general structural form, as well as providing scope for the installation of diverse achiral and chiral appendages and potential biomolecular-interacting elements around the core macrocyclic ring architectures. The use of different macrocyclisation techniques in the DOS should also offer an expansion in the number of distinct molecular scaffolds accessible from a given set of building blocks (relative to strategies which employ only one method of ring-closure). Furthermore each method of macrocyclisation should furnish product scaffolds containing different characteristic structural motifs. In the case of ringclosure by 1,3-dipolar cycloaddition, the resulting products 14 will contain a triazole ring system, a structural unit which is considered to act as a peptide bond mimic (both the trans-and the cis-amide bond configurations can be mimicked by the 1,4-and 1,5-triazoles, respectively). 14, 29, 36, 37 Thus, such products can be considered to be macrocyclic peptidomimetics, a sub-class of macrocycles which is of considerable interest in drug discovery and which has attracted significant attention in recent years. 14, 38 Macrocyclisation by ringclosing and ene-yne metathesis would furnish products containing synthetically versatile functional motifs (alkene and diene units, respectively) that could potentially serve as synthetic handles for further derivitisation around the macrocyclic cores. General structural type 15 is non-peptidic, a sub-class of macrocyles which is comparatively less-well explored in drug discovery. 10 
Proof of concept work
In order to establish the validity of the DOS strategy, the synthesis of a representative member of each of the three different general macrocyclic structural types 14e16 was targeted. We specifically chose compounds 19e21, which we envisaged could be generated from building blocks 22e29 and 9 (Scheme 2).
In addition to demonstrating the feasibility of the DOS, these specific compounds were selected as targets in order to probe both the synthetic versatility of the DOS and also its' capacity to furnish macrocyles with certain interesting or desirable structural characteristics. The target compounds covered a range of macrocyclic ring sizes and included both cyclic and acyclic amine motifs, as well as other functionalities and potential biomolecular interacting elements (e.g., hydrogen bond donors and acceptors). Each target macrocycle also included a chiral centre, which we assumed could be introduced through the use of chiral 'carbonyl capping' building blocks (23, 26 and 28) . If successful, this would demonstrate another method to introduce stereochemical diversity into the macrocycles through the building blocks (in addition to variation in the scaffold-defining elements), which should facilitate the probing of three-dimensional chemical space around the ring architectures. Target compounds 19 and 20 contained aryl halide motifs, which could potentially be further functionalised via various metalcatalysed cross-coupling processes. Successful synthesis of 19 would thus demonstrate that a functional group handle for derivitisation around the macrocyclic core could be introduced into compounds of the general form 14. In the case of the representative example of macrocyles of the general form 20, it was thought that it would be interesting to examine whether an additional synthetic handle for post-cyclisation structural elaboration could be installed which was orthogonal to the alkene unit introduced during macrocyclisation.
2.2.1. Building block synthesis. Building blocks 9, 22, 25, 27 and 29 could be obtained from commercial sources. Amino-alkyne building block 23 was readily accessed from commercially available pyridine-acid 29 in three steps (Scheme 3). Amine protection generated the N-Boc derivative 30. Propyl phosphonic acid anhydride (T3P) mediated coupling with alkynyl amine 31 furnished compound 32 and subsequent removal of the Boc group under acidic conditions yielded the desired building block 23 (isolated as the HCl-salt). Building block 28 could also be accessed (again as the corresponding HCl-salt) from 30 by EDC-mediated coupling with alkynyl alcohol 33 to form 34 followed by Boc deprotection. The synthesis of acyclic amino-alkene 26 was similarly straightforward. EDC-mediated coupling of commercially available carboxylic acid 35 and alkenyl alcohol 36 proceeded smoothly to generate ester 37 and subsequent acid-mediated Boc group removal afforded the target building block 26 (isolated as the HCl-salt). It was envisaged that azido-bromo 'hydroxyl capping' building block 24 could be generated in situ from the corresponding tosylate derivative 38 when required (see Section 2.2.2) which in turn was readily obtained from alcohol 39.
Synthesis of target compound 19. The synthesis of compound
19 commenced with the esterification of hydroxy benzoic acid 'platform' building block 22 to generate compound 40 (Scheme 4). Coupling with 'hydroxyl capping' building block 24 (which was formed in situ from 38), proceeded smoothly to afford compound 41. Subsequent saponification of the ester moiety under basic conditions provided derivative 42. 39 Coupling with amine 'carbonyl capping' building block 23 provided linear cyclization precursor 43 in a good yield. Pleasingly, 1,3-dipolar cycloaddition with copper catalysis proceeded smoothly and with a high degree of regioselectivity to furnish target macrocycle derivative 19 in a good yield. 40 The cycloaddition of 43 under ruthenium catalysis was investigated in an attempt to generate the regioisomeric macrocycle containing the 1,5-disubstituted triazole ring system. Although there was evidence for the formation of the desired product, it could not be isolated. Attention then turned towards the use of the alternative 'carbonyl capping' building block 44 in the DOS of compounds of the form 14. Compound 44 was readily prepared from L-proline by an analogous route to the preparation of 23 (see Experimental Section). Coupling of 42 with 44 afforded acyclic precursor 45 in a high yield. Pleasingly, subsequent macrocyclisation under coppercatalysis again proceeded smoothly to furnish compound 46, another macrocycle of the general form 14.
2.2.3. Synthesis of target compounds 20 and 21 from salicylaldehyde 25. It was anticipated that target macrocyclic compounds 20 and 21 could both be accessed from salicylaldehyde 25 (Scheme 5). Attachment of the appropriate 'hydroxyl capping' building blocks 27 or 29 (couple stage) proceeded smoothly to furnish compounds 47 and 48. Reductive amination of 47 with 'carbonyl capping' building block 26 furnished cyclization precursor 49. In the par stage of the synthesis, the ring-closing metathesis of 49 with Hoveyda-Grubbs second generation catalyst was attempted, but no product formation was observed. It was thought that the lack of reactivity might be the result of deactivation of the metathesis catalyst via coordination to the free amine of substrate 49. Thus, metathesis was attempted with the addition of one equivalent of p-toluenesulfonic acid hydrate (PTSA$H 2 O) to the reaction mixture in order to protonate the amine in situ. Pleasingly, this allowed access to target macrorycle 20, albeit in a low yield (which was attributed to incomplete consumption of the starting material, despite the prolonged reaction time). Knoevenagel condensation of 48 with 'spacer' building block 9 (the second couple stage) afforded compound 50 and subsequent coupling with 'carbonyl capping' building block 28 (the third couple stage) led to the formation of macrocyclisation precursor 51. In the pair stage of the synthesis, intramolecular ene-yne metathesis successfully afforded target compound 21. The isolated yield of 21 was relatively low, which again could be attributed to incomplete consumption of starting material.
Conclusions
Herein, we have described a new strategy for the expedient DOS of novel and structurally diverse macrocyclic compounds which are based around a variety of distinct molecular scaffolds. The synthetic approach is based around the use of aromatic starting materials that bear an electrophilic carbonyl group and a nucleophilic hydroxyl group. These are designed to serve as 'platforms' onto which different building blocks can be attached to afford a range of distinct acyclic precursors. Subsequent intramolecular cyclisation reactions would then furnish different macrocyclic compounds. It was anticipated that the new DOS strategy would allow access to macrocyclic compounds of the general structural forms 14e16. In a proof-of-concept study, the synthesis of four different novel macrocyclic compounds 19e21 and 46, including representative examples of each of the different macrocyclic structural forms, was achieved. Each of these four previously unreported compounds was based around a distinct macrocyclic scaffold and contains functional motifs that could potentially interact with biological targets. These compounds are of significant interest from both a biological and synthetic perspective and their successful generation provides a validation of our new DOS strategy for the synthesis of structurally diverse macrocycles. We anticipate that this approach holds significant potential for library generation. It is step-efficient, proceeds from readily available starting materials and is modular in nature, which should allow for concise access to a diverse range of molecular scaffolds through variation in the building blocks attached to the core aromatic unit. The DOS strategy also features the use of three different macrocyclisation techniques, which allows for potential access to different structural motifs embedded within the macrocyclic architectures. Thus, we believe that this new DOS strategy represents a valuable contribution to the repertoire of strategies available for the synthesis of the biologically interesting macrocycle compound class. Larger library synthesis endeavours using this DOS algorithm are on-going. These, and the results of subsequent biological screening studies (which we hope will lead to the identification of novel antibacterial agents), will be reported in due course.
Experimental section
General information
All reagents and solvents were purchased from commercial sources and used without further purification unless otherwise stated. All the experiments were carried out under a nitrogen atmosphere unless otherwise stated. Melting points were measured using a B€ uchi B545 melting point apparatus and are uncorrected. Thin layer chromatography (TLC) was performed on precoated Merck silica gel GF 254 plates. IR spectra were recorded on a PerkineElmer Spectrum One (FT-IR) spectrophotometer. Flash column chromatography was performed on silica gel (230e400 mesh). 
Synthesis of but-3-en-1-yl Boc-4-iodo-L-phenylalanine (37).
To a stirred solution of Boc-4-iodo-L-phenylalanine (2.00 g, 5.11 mmol) in CH 2 Cl 2 (20 mL) was added EDC (2.34 g, 12.2 mmol), DMAP (183 mg, 1.50 mmol) and 3-buten-1-ol (1.20 mL) at 0 C. The solution was warmed to rt and stirred for 19 h. The solution was diluted with CH 2 Cl 2 (50 mL) and the organic phase washed with 5% NaHCO 3 (50 mL), H 2 O (30 mL) and then brine (30 mL). The organic extract was dried (MgSO 4 ) and the crude product purified by flash column chromatography eluting with 50% EtOAc in hexane to yield the title compound as crystalline, yellow solid (1.70 g, 75%). These data are consistent with those previously reported. 4.2.14. Synthesis of (S)-N-(prop-2-yn-1-yl)proline carboxamide hydrochloride (44). To a stirred solution of L-proline (5.00 g, 43.4 mmol) in THF (325 mL) and H 2 O (325 mL), Na 2 CO 3 (17.3 g, 162 mmol) was added at rt and the resultant solution cooled to 0 C. Following the addition of Boc-anhydride (10.4 g, 47.8 mmol), the solution was stirred at 0 C for 2 h and then at rt for 18 h. The THF was removed under reduced pressure and the resulting aqueous solution acidified with 1M HCl to pH 4. The aqueous layer was extracted with EtOAc (3Â50 mL) and the organic extracts were combined and dried (Na 2 SO 4 ). The solvent was removed under reduced pressure to yield N-Boc-L-proline. To a stirred solution of N-Boc-L-proline (2.00 g, 9.29 mmol) in EtOAc (70 mL), propargylamine (31) (600 mL, 9.34 mmol) was added at rt and then cooled to 0 C. To this solution was added DIPEA (3.2 mL, 18.8 mmol) and a solution of 50 wt. % T3P in EtOAc (7.25 mL, 12.2 mmol). The solution was stirred at 0 C for 30 min before being stirred at rt for 20 h. The reaction was quenched with H 2 O (50 mL), EtOAc (50 mL) was added and the organic layer separated and washed with 5% NaHCO 3 (50 mL), 5% citric acid (50 mL) and brine (50 mL). The organic extract was dried (MgSO 4 ) and the solvent removed under reduced pressure to yield (S)-1-Boc-(prop-2-yn-1-yl)proline carboxamide.
Synthesis of azido-alkyne (43). (S)-N-(prop
(S)-1-Boc-(prop-2-yn-1-yl)proline carboxamide (734 mg, 2.80 mmol) was dissolved in 4N HCl in 1,4-dioxane (26 mL) and stirred at rt for 2 h after which the solvent was removed under reduced pressure to yield the crude product as a brown solid. The crude product with triturated with chloroform to yield the title compound as a white salt (470 mg, 47% over three steps). IR n max (neat)/cm The reaction was subsequently reluxed at 55 C for 16 h. The reaction was quenched with NaHCO 3 (30 mL) and the solvent removed under reduced pressure. The aqueous layer was extracted with CH 2 Cl 2 , after which the organic phases were combined, washed with brine (30 mL) and dried (MgSO 4 ). The crude product was purified by flash column chromatography, eluting with 30% EtOAc in petroleum ether 30e40 to yield the title compound as a colourless oil (9.0 mg, 26% To a stirred solution of 48 (1.18 g, 6 .76 mmol) in toluene (120 mL) was added malonic acid (9) (780 mg, 7.45 mmol), pyridine (610 mL, 7.57 mmol) and piperidine (160 mL, 1.62 mmol). The solution was refluxed at 120 C with a DeaneStark apparatus for 20 h. The reaction was quenched with 3M HCl and the solvent removed under reduced pressure. H 2 O (50 mL) was added and the aqueous layer extracted with EtOAc (2Â50 mL). The organic layers were combined, washed with brine (50 mL), dried (Na 2 SO 4 ) and the solvent removed under reduced pressure. The crude product was purified with flash column chromatography, eluting with a gradient from 20% to 30% EtOAc in hexane and then with 10% MeOH in EtOAc to yield the title compound as an amorphous orange solid (943 mg, 64% The solution was stirred at 0 C for 30 min and rt for 18 h. The reaction was quenched with H 2 O (100 mL) and EtOAc (100 mL) was added. The organic layer was separated and washed with 5% NaHCO 3 (2Â100 mL), 5% citric acid (100 mL) and then brine (70 mL). The organic extract was dried (MgSO 4 ) and the solvent removed under reduced pressure to yield the title compound as a colourless oil (280 mg, 72% 
